The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | Campbell Shannon | Director | Grant(A) | 40K | — | $0 |
| Jun 26, 2026 | Raman Prakash | Director | Grant(A) | 40K | — | $0 |
| Jun 26, 2026 | Behbahani Ali | Director | Grant(A) | 40K | — | $0 |
| Jun 26, 2026 | Kulkarni Samarth | Director | Grant(A) | 40K | — | $0 |
| Jun 26, 2026 | Menzel Garry E | Director | Grant(A) | 40K | — | $0 |
| Jun 26, 2026 | Dhingra Kapil | Director | Grant(A) | 40K | — | $0 |
| Jun 19, 2026 | Raman Prakash | Director | Grant(A) | 8K | $1.66 | $13K |
| Jun 19, 2026 | Behbahani Ali | Director | Grant(A) | 9K | $1.66 | $15K |
| Mar 20, 2026 | Behbahani Ali | Director | Grant(A) | 7K | $2.15 | $15K |
| Mar 20, 2026 | Raman Prakash | Director | Grant(A) | 6K | $2.15 | $13K |
| Jan 21, 2026 | Hatzis-Schoch Brent | SEE REMARKS | Grant(A) | 250K | — | $0 |
| Jan 21, 2026 | Yurasov Sergey | CHIEF MEDICAL OFFICER | Grant(A) | 250K | — | $0 |
| Jan 21, 2026 | Velleca Mark A. | PRESIDENT & CEO, Director | Grant(A) | 600K | — | $0 |
| Jan 21, 2026 | Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | Grant(A) | 250K | — | $0 |
| Jan 21, 2026 | Jones Erika | SEE REMARKS | Grant(A) | 200K | — | $0 |
| Dec 12, 2025 | Behbahani Ali | Director | Grant(A) | 5K | $2.76 | $14K |
| Dec 12, 2025 | Raman Prakash | Director | Grant(A) | 5K | $2.76 | $13K |
| Sep 19, 2025 | Behbahani Ali | Director | Grant(A) | 4K | $3.35 | $14K |
| Sep 19, 2025 | Raman Prakash | Director | Grant(A) | 4K | $3.35 | $13K |
| Jun 20, 2025 | Behbahani Ali | Director | Grant(A) | 6K | $2.33 | $14K |
| Jun 20, 2025 | Raman Prakash | Director | Grant(A) | 6K | $2.33 | $13K |
| Jun 12, 2025 | Behbahani Ali | Director | Grant(A) | 31K | — | $0 |
| Jun 12, 2025 | Kulkarni Samarth | Director | Grant(A) | 31K | — | $0 |
| Jun 12, 2025 | Dhingra Kapil | Director | Grant(A) | 31K | — | $0 |
| Jun 12, 2025 | Campbell Shannon | Director | Grant(A) | 31K | — | $0 |
| Jun 12, 2025 | Raman Prakash | Director | Grant(A) | 31K | — | $0 |
| Jun 12, 2025 | Menzel Garry E | Director | Grant(A) | 31K | — | $0 |
| Mar 21, 2025 | Behbahani Ali | Director | Grant(A) | 8K | $1.88 | $14K |
| Mar 21, 2025 | Raman Prakash | Director | Grant(A) | 7K | $1.88 | $13K |
| Mar 19, 2025 | Biotech Growth N V | 10% Owner | Sell(S) | 400K | $2.09 | $836K |
| Mar 19, 2025 | Biotech Growth N V | 10% Owner | Sell(S) | 500K | $2.12 | $1.1M |
| Mar 19, 2025 | Biotech Growth N V | 10% Owner | Sell(S) | 1.0M | $2.07 | $2.1M |
| Mar 19, 2025 | Biotech Growth N V | 10% Owner | Sell(S) | 2.0M | $2.00 | $4.0M |
| Mar 19, 2025 | Biotech Growth N V | 10% Owner | Sell(S) | 1.0M | $2.31 | $2.3M |
| Mar 19, 2025 | Biotech Growth N V | 10% Owner | Sell(S) | 300K | $1.94 | $582K |
| Mar 19, 2025 | Biotech Growth N V | 10% Owner | Sell(S) | 584K | $1.95 | $1.1M |
| Jan 30, 2025 | Hatzis-Schoch Brent | SEE REMARKS | Grant(A) | 75K | — | $0 |
| Jan 30, 2025 | Hatzis-Schoch Brent | SEE REMARKS | Grant(A) | 175K | — | $0 |
| Jan 30, 2025 | Jones Erika | SEE REMARKS | Grant(A) | 75K | — | $0 |
| Jan 30, 2025 | Jones Erika | SEE REMARKS | Grant(A) | 125K | — | $0 |
| Jan 30, 2025 | Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | Grant(A) | 75K | — | $0 |
| Jan 30, 2025 | Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | Grant(A) | 175K | — | $0 |
| Jan 30, 2025 | Yurasov Sergey | CHIEF MEDICAL OFFICER | Grant(A) | 75K | — | $0 |
| Jan 30, 2025 | Yurasov Sergey | CHIEF MEDICAL OFFICER | Grant(A) | 200K | — | $0 |
| Jan 30, 2025 | Velleca Mark A. | PRESIDENT & CEO, Director | Grant(A) | 75K | — | $0 |
| Jan 30, 2025 | Velleca Mark A. | PRESIDENT & CEO, Director | Grant(A) | 500K | — | $0 |
| Dec 13, 2024 | Behbahani Ali | Director | Grant(A) | 6K | $2.50 | $14K |
| Dec 13, 2024 | Campbell Shannon | Director | Grant(A) | 5K | $2.50 | $11K |
| Dec 13, 2024 | Raman Prakash | Director | Grant(A) | 5K | $2.50 | $13K |
| Sep 20, 2024 | Behbahani Ali | Director | Grant(A) | 3K | $4.78 | $14K |
| Sep 20, 2024 | Raman Prakash | Director | Grant(A) | 3K | $4.78 | $13K |
| Sep 20, 2024 | Campbell Shannon | Director | Grant(A) | 2K | $4.78 | $11K |
| Aug 28, 2024 | Versant Voyageurs I Parallel, L.P. | 10% Owner | Sell(S) | 222K | $6.32 | $1.4M |
| Jun 21, 2024 | Behbahani Ali | Director | Grant(A) | 3K | $4.98 | $14K |
| Jun 21, 2024 | Campbell Shannon | Director | Grant(A) | 2K | $4.98 | $10K |
| Jun 21, 2024 | Raman Prakash | Director | Grant(A) | 2K | $4.98 | $11K |
| Jun 6, 2024 | Behbahani Ali | Director | Grant(A) | 31K | — | $0 |
| Jun 6, 2024 | Dhingra Kapil | Director | Grant(A) | 31K | — | $0 |
| Jun 6, 2024 | Campbell Shannon | Director | Grant(A) | 31K | — | $0 |
| Jun 6, 2024 | Raman Prakash | Director | Grant(A) | 31K | — | $0 |
| Jun 6, 2024 | Menzel Garry E | Director | Grant(A) | 31K | — | $0 |
| Jun 6, 2024 | Kulkarni Samarth | Director | Grant(A) | 31K | — | $0 |
| Apr 10, 2024 | Raman Prakash | Director | Grant(A) | 61K | — | $0 |
| Apr 10, 2024 | Campbell Shannon | Director | Grant(A) | 61K | — | $0 |
| Mar 15, 2024 | Behbahani Ali | Director | Grant(A) | 3K | $4.54 | $14K |
| Mar 15, 2024 | Dixon Wendy L | Director | Grant(A) | 3K | $4.54 | $15K |
| Feb 14, 2024 | Jones Erika | SEE REMARKS | Grant(A) | 100K | — | $0 |
| Feb 14, 2024 | Velleca Mark A. | PRESIDENT & CEO, Director | Grant(A) | 537K | — | $0 |
| Feb 14, 2024 | Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | Grant(A) | 200K | — | $0 |
| Feb 14, 2024 | Yurasov Sergey | CHIEF MEDICAL OFFICER | Grant(A) | 225K | — | $0 |
| Feb 14, 2024 | Hatzis-Schoch Brent | SEE REMARKS | Grant(A) | 200K | — | $0 |
| Feb 14, 2024 | Ni Fang | SEE REMARKS | Grant(A) | 200K | — | $0 |
| Dec 15, 2023 | Behbahani Ali | Director | Grant(A) | 4K | $2.73 | $12K |
| Dec 15, 2023 | Dixon Wendy L | Director | Grant(A) | 4K | $2.73 | $11K |
| Oct 17, 2023 | Biotech Growth N V | 10% Owner | Buy(P) | 400K | $2.34 | $936K |
| Sep 17, 2023 | Velleca Mark A. | PRESIDENT & CEO, Director | Grant(A) | 1.0M | — | $0 |
| Sep 15, 2023 | Behbahani Ali | Director | Grant(A) | 3K | $3.60 | $12K |
| Sep 15, 2023 | Dixon Wendy L | Director | Grant(A) | 3K | $3.60 | $11K |
| Sep 15, 2023 | Velleca Mark A. | PRESIDENT & CEO, Director | Grant(A) | 5K | $3.60 | $19K |
| Jul 5, 2023 | Ra Capital Management, L.P. | Director | Buy(P) | 936K | $5.00 | $4.7M |
| Jul 5, 2023 | Behbahani Ali | Director | Buy(P) | 1.0M | $5.00 | $5.0M |
| Jun 30, 2023 | BB Biotech AG | 10% Owner | Buy(P) | 1.0M | $5.00 | $5.0M |
| Jun 27, 2023 | Biotech Growth N V | 10% Owner | Buy(P) | 1.7M | $5.49 | $9.6M |
| Jun 27, 2023 | Epstein David M. | SEE REMARKS, Director | Sell(S) | 25K | $6.70 | $168K |
| Jun 16, 2023 | Behbahani Ali | Director | Grant(A) | 6K | $2.10 | $12K |
| Jun 16, 2023 | Velleca Mark A. | Director | Grant(A) | 9K | $2.10 | $19K |
| Jun 16, 2023 | Dixon Wendy L | Director | Grant(A) | 5K | $2.10 | $11K |
| May 16, 2023 | Behbahani Ali | Director | Grant(A) | 17K | — | $0 |
| May 16, 2023 | Dhingra Kapil | Director | Grant(A) | 17K | — | $0 |
| May 16, 2023 | Dixon Wendy L | Director | Grant(A) | 17K | — | $0 |
| May 16, 2023 | Kulkarni Samarth | Director | Grant(A) | 17K | — | $0 |
| May 16, 2023 | Menzel Garry E | Director | Grant(A) | 17K | — | $0 |
| May 16, 2023 | Velleca Mark A. | Director | Grant(A) | 17K | — | $0 |
| May 16, 2023 | Shah Rajeev M. | Director | Grant(A) | 17K | — | $0 |
| May 16, 2023 | Mayweg Alexander | Director | Grant(A) | 17K | — | $0 |
| Mar 16, 2023 | Behbahani Ali | Director | Grant(A) | 7K | $1.67 | $12K |
| Mar 16, 2023 | Velleca Mark A. | Director | Grant(A) | 11K | $1.67 | $19K |
| Mar 16, 2023 | Dixon Wendy L | Director | Grant(A) | 6K | $1.67 | $11K |
| Feb 13, 2023 | Hatzis-Schoch Brent | SEE REMARKS | Grant(A) | 200K | — | $0 |
| Feb 13, 2023 | Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | Grant(A) | 200K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).